U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist.
IC50&Target
TXA2
体外研究
U-46619 (1 nM-10 μM) causes platelets shape change and aggregation in a concentration-dependent manner, and with EC50s of 0.58 μM and 0.013 μM for aggregation and shape change, respectively.
U-46619 (10 nM-10 μM) increases internal Ca concentration ([Ca]i) and activates phosphoinositide (PI) hydrolysis in a concentration-dependent manner with a similar concentration-dependency.
U-46619 (3 nM-10 μM) also activates GTPase concentration-dependently in the membranes derived from platelets.
U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways.
体内研究
U-46619 (5 μg/kg; i.v.) increases blood pressure in male spontaneously hypertensive rats (SHR).
Animal Model:
12-15 weeks-old male and female SHR
Dosage:
5 μg/kg
Administration:
Intravenous injection
Result:
Induceed a significant increase of MABP after 1 min in male SHR.
分子式
C21H34O4
分子量
350.49
CAS号
56985-40-1
运输条件
Room temperature in continental US; may vary elsewhere.